• IBDV VP3-Driven IRF7 Degradation: Ubiquitin-Proteasome Mecha

  2026-05-28

  This study reveals that infectious bursal disease virus (IBDV) exploits its VP3 protein to promote the proteasomal degradation of interferon regulatory factor 7 (IRF7), suppressing the host's type I interferon response and facilitating viral replication. These findings illuminate a novel immune evasion strategy and underscore the centrality of ubiquitin-proteasome system modulation in host-pathogen interactions.

• Annexin V-FITC/PI Apoptosis Assay Kit: Precision in Hepatic

  2026-05-27

  Explore how the Annexin V-FITC/PI Apoptosis Assay Kit enables high-resolution apoptosis detection in liver injury and transplantation research. Learn why this APExBIO solution is uniquely suited for mechanistic studies of hepatocyte apoptosis, with insights bridging peptidomics and translational assay design.

• Lactobacillus gasseri Enhances Intestinal Barrier via NR1I3–

  2026-05-27

  Qian et al. (2024) demonstrate that Lactobacillus gasseri ATCC33323 alleviates DSS-induced colitis in mice by regulating intestinal E-cadherin expression through NR1I3. This mechanistic insight advances understanding of probiotic interventions for IBD and highlights E-cadherin as a critical mediator in maintaining mucosal barrier integrity.

• Otilonium Bromide: Antimuscarinic Agent for Cholinergic Path

  2026-05-26

  Otilonium Bromide is a high-purity antimuscarinic agent used to modulate cholinergic signaling pathways in neuroscience and smooth muscle research. Its robust solubility and selectivity enable reproducible inhibition of acetylcholine receptors, facilitating precise experimental workflows. APExBIO supplies Otilonium Bromide (SKU: B1607) as both a powder and 10 mM solution, supporting diverse in vitro applications.

• Afatinib (BIBW 2992) in Patient-Derived Assembloid Research

  2026-05-26

  Afatinib’s irreversible inhibition of EGFR, HER2, and HER4 uniquely empowers physiologically relevant assembloid models for cancer biology research. This guide demystifies practical workflows and troubleshooting strategies, integrating the latest breakthroughs in patient-derived tumor modeling.

• 3-(1-methylpyrrolidin-2-yl)pyridine (N2703): Precision Tools

  2026-05-25

  Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) advances the study of adipose-neural interactions and cardiac arrhythmia. This article uncovers new experimental frameworks and protocol insights that set it apart from prior reviews.

• ATRX Loss Sensitizes High-Grade Glioma to RTK and PDGFR Inhi

  2026-05-25

  The reference study identifies that high-grade glioma cells deficient in the chromatin remodeler ATRX are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. This finding highlights the need to factor ATRX mutation status into experimental design and clinical trial interpretation for targeted therapies in gliomas.

• Strategic Apoptosis Quantification: Translating Mechanism to

  2026-05-24

  This thought-leadership article delivers a rigorous exploration of how precise apoptosis quantification—anchored by the Annexin V-FITC/PI Apoptosis Assay Kit—empowers translational researchers to bridge mechanistic insight with actionable therapeutic strategies. Drawing on the latest advances in phosphatidylserine externalization detection, flow cytometry, and infection-driven wound healing, the discussion integrates new evidence from nano-therapeutic research against Pseudomonas aeruginosa and situates the APExBIO platform at the nexus of apoptosis research and clinical innovation. Detailed protocol guidance, competitive benchmarking, and an evidence-based outlook are provided.

• Cimetidine Applications: Advanced Workflows in Cancer and BB

  2026-05-23

  Cimetidine stands out as a versatile histamine-2 receptor antagonist, uniquely positioned for both cancer research and blood-brain barrier (BBB) permeability assays. Explore how its robust solubility, partial agonist activity, and validated purity empower high-throughput and reproducible experimental workflows.

• Maraviroc (UK-427857): Mechanistic Insights and Translationa

  2026-05-22

  Discover how Maraviroc, a selective CCR5 antagonist, advances both HIV-1 entry inhibition and neuroinflammation modulation. This article uniquely explores mechanistic details and translational strategies for Maraviroc in experimental and clinical research.

• Praeruptorin A Suppresses Poly (I:C)-Induced Inflammatory Pa

  2026-05-22

  The reference study demonstrates Praeruptorin A's ability to inhibit NF-κB activation and key inflammatory gene expression in poly (I:C)-stimulated RAW264.7 macrophages. These findings provide mechanistic insight into NF-κB-targeted anti-inflammatory strategies and inform the design of inflammation assay models relevant for viral and immune response research.

• Cytoskeleton-Dependent Autophagy Under Mechanical Stress

  2026-05-21

  This study demonstrates that mechanical stress-induced autophagy in human cells critically depends on cytoskeletal microfilaments, with microtubules playing a supportive role. These findings clarify the mechanotransduction pathway, informing future experimental approaches in cell signaling and cancer research.

• Epalrestat: Expanding Neuroprotection Beyond Diabetic Models

  2026-05-21

  Explore Epalrestat as an advanced aldose reductase inhibitor for oxidative stress research and neurodegenerative disease models. This article delivers a unique, in-depth analysis of KEAP1/Nrf2 pathway activation and practical assay considerations.

• AG-221 (Enasidenib): Systems Biology Insights for IDH2-Mutan

  2026-05-20

  Explore how AG-221 (Enasidenib) enables integrated, systems-level research on IDH2-mutant acute myeloid leukemia. This article offers original analysis on metabolic rewiring, resistance, and practical assay design—distinguishing it from existing protocol-centric guides.

• SM-102: Optimizing mRNA Delivery with Advanced Lipid Nanopar

  2026-05-20

  SM-102 stands out as a high-purity ionizable lipid engineered to enhance mRNA vaccine delivery through lipid nanoparticles. This guide walks researchers through real-world protocol improvements, data-driven comparative insights, and actionable troubleshooting to unlock reproducible, high-efficiency mRNA delivery for both vaccine and therapeutic applications.

7700 records 17/514 page Previous Next First page 上5页 1617181920 下5页 Last page